Kelly Knupp, AES 2020 – Fenfluramine for the Treatment of Seizures Associated with Lennox-Gastaut Syndrome
We caught up with Kelly Knupp (University of Colorado, Anschutz Medical Campus, Children’s Hospital Colorado, CO, USA) to discuss the use of fenfluramine for the reduction of seizures associated with Lennox-Gastaut syndrome. (Clinical Trial Identifier: NCT03355209). The abstract ‘Efficacy and safety of FINTEPLA (fenfluramine) for the treatment of seizures associated with Lennox-Gastaut syndrome: a randomized, double-blind, placebo-controlled clinical trial.’ (ABSTRACT NUMBER: 852) was presented at the virtual AES 2020, 4-8 December 2020.
Questions
- Could you tell us a little about Lennox-Gastaut syndrome (LGS) and the unmet needs in its treatment? (0:15)
- What is the rationale for the use of fenfluramine in the treatment of LGS? (1:45)
- What were the aims and design of the recent Phase III study investigating fenfluramine in the treatment of LGS? (2:23)
- What were the efficacy and safety findings of this study? (3:59)
Disclosures: Kelly G Knupp has received research funding from: zogenix, west therapeutics, stoke, encoded, eisai and consulting fees from: The epilepsy study consortium, zogenix, stoke, encoded, eisai, GW, arena, epygenix.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of AES 2020, 4-8 December, 2020 (Virtual).
